Mylan is engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (OTC) pharmaceutical products for resale by others and active pharmaceutical ingredients (API) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Co.'s API business is conducted through its subsidiary, Mylan Laboratories Limited, which is included within its Rest of World segment. Among Co.'s branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. Co.'s OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products.
|
Free MYL Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.73 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: MYL Stock Forecast Based on Zacks ABR data; powered by Xignite |